Zoetis (XSWX:ZTS) Research & Development: CHF576 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:ZTS Zoetis Inc XSWX:ZTS
63 GF Score
Price CHF61.79
GF Value CHF156.38
Valuation Significantly Undervalued
View Full Analysis

What is Zoetis Research & Development?

Zoetis XSWX:ZTS +2.39% 63 Research & Development is CHF576 Mil as of Mar. 2026. GuruFocus rates XSWX:ZTS with a GF Score™ of 63/100 and a GF Value™ of CHF156.38 (Significantly Undervalued).

Research & Development is the aggregate amount of research and development expenses during the year. Zoetis's Research & Development for the three months ended in Mar. 2026 was CHF142 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was CHF576 Mil.

Zoetis  (XSWX:ZTS) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Zoetis Research & Development Related Terms

Zoetis Research & Development Historical Data

* Premium members only.

The historical data trend for Zoetis's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zoetis Research & Development Chart

Zoetis Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 467.87 502.13 530.99 611.64 556.24

Zoetis Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 143.14 139.87 135.34 158.58 141.71
XSWX:ZTS
63GF Score
Zoetis Inc XSWX:ZTS
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zoetis Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF576 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of CHF576 Mil mean?
Zoetis (XSWX:ZTS) has a Research & Development of CHF576 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Zoetis and its competitors.
Is Zoetis' Research & Development too high?
Zoetis' current Research & Development is CHF576 Mil. Overall, Zoetis has a GF Score™ of 63/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Zoetis' Research & Development compare to UTHR and VTRS?
Zoetis' Research & Development of CHF576 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Drug Manufacturers company?
A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Zoetis and its competitors. Zoetis's current Research & Development is CHF576 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zoetis stock overvalued right now?
Based on GuruFocus' analysis, Zoetis (XSWX:ZTS) is currently considered Significantly Undervalued. The stock's GF Value™ is CHF156.38, compared to a current price of CHF61.79 — trading 60.5% below its estimated fair value. The current Research & Development is CHF576 Mil. Zoetis' overall GF Score™ is 63/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Zoetis (XSWX:ZTS), the current Research & Development is CHF576 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Zoetis (XSWX:ZTS) Overvalued in 2026?

Based on GuruFocus' analysis, Zoetis stock appears to be undervalued. The current stock price of CHF61.79 is trading 60.5% below its estimated GF Value™ of CHF156.38. GuruFocus considers Zoetis to be Significantly Undervalued.

Key valuation signals for XSWX:ZTS:

  • Research & Development: CHF576 Mil
  • GF Value™: CHF156.38 vs. price of CHF61.79 (60.5% below fair value)
  • GF Score™: 63/100

No single metric tells the full story. See the XSWX:ZTS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Zoetis Business Description

Address 10 Sylvan Way, Parsippany, NJ, USA, 07054
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 65% from companion animal (dogs, horses, cats) products. Its US business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
63GF Score

Get the complete analysis for XSWX:ZTS

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF61.79
Price
CHF156.38
GF Value